Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968053168> ?p ?o ?g. }
- W1968053168 endingPage "716" @default.
- W1968053168 startingPage "709" @default.
- W1968053168 abstract "Background & Aims Patterns of serum hepatitis B surface antigen (HBsAg) decline during nucleos(t)ide analogue (NA) therapy have not been well investigated. Methods We determined the cumulative serologic, virologic, and biochemical outcomes of 142 Asian CHB patients, with at least 6 months exposure to other NAs, receiving tenofovir with or without lamivudine for up to 3 years. Liver biochemistry, serum HBV DNA, and HBsAg levels were determined at baseline, 6 months and yearly from years 1 to 3. Results 142, 123 (86.6%), and 70 (49.3%) CHB patients were followed up for 1, 2, and 3 years, respectively. Two phases of HBsAg decline were observed. Patients with baseline HBsAg ⩾3 log IU/ml, when compared to patients with baseline HBsAg <3 log IU/ml, had a greater median rate of HBsAg reduction through 3 years of treatment (0.155 and 0.039 log IU/ml/year respectively, p <0.001). Among patients with 3 years of follow-up, there was a significantly greater median rate of HBsAg reduction during the first year when compared to the second and third years (0.220, 0.136, and 0.081 log IU/ml/year respectively, p <0.001). HBeAg status, HBV genotype, and concomitant lamivudine therapy were not important determinants of HBsAg kinetics (all p >0.05). The 3-year cumulative virologic suppression rate was 93.3%, with no cases of resistance detected. Conclusions Serum HBsAg levels in NA-experienced patients receiving tenofovir demonstrated a variable pattern of decline, with slower rates of reduction noted in patients with lower baseline HBsAg levels, and could explain the rarity of HBsAg seroclearance during NA therapy. Patterns of serum hepatitis B surface antigen (HBsAg) decline during nucleos(t)ide analogue (NA) therapy have not been well investigated. We determined the cumulative serologic, virologic, and biochemical outcomes of 142 Asian CHB patients, with at least 6 months exposure to other NAs, receiving tenofovir with or without lamivudine for up to 3 years. Liver biochemistry, serum HBV DNA, and HBsAg levels were determined at baseline, 6 months and yearly from years 1 to 3. 142, 123 (86.6%), and 70 (49.3%) CHB patients were followed up for 1, 2, and 3 years, respectively. Two phases of HBsAg decline were observed. Patients with baseline HBsAg ⩾3 log IU/ml, when compared to patients with baseline HBsAg <3 log IU/ml, had a greater median rate of HBsAg reduction through 3 years of treatment (0.155 and 0.039 log IU/ml/year respectively, p <0.001). Among patients with 3 years of follow-up, there was a significantly greater median rate of HBsAg reduction during the first year when compared to the second and third years (0.220, 0.136, and 0.081 log IU/ml/year respectively, p <0.001). HBeAg status, HBV genotype, and concomitant lamivudine therapy were not important determinants of HBsAg kinetics (all p >0.05). The 3-year cumulative virologic suppression rate was 93.3%, with no cases of resistance detected. Serum HBsAg levels in NA-experienced patients receiving tenofovir demonstrated a variable pattern of decline, with slower rates of reduction noted in patients with lower baseline HBsAg levels, and could explain the rarity of HBsAg seroclearance during NA therapy." @default.
- W1968053168 created "2016-06-24" @default.
- W1968053168 creator A5029035458 @default.
- W1968053168 creator A5030193303 @default.
- W1968053168 creator A5031848511 @default.
- W1968053168 creator A5038617642 @default.
- W1968053168 creator A5066110089 @default.
- W1968053168 creator A5069529197 @default.
- W1968053168 creator A5083700089 @default.
- W1968053168 creator A5091803938 @default.
- W1968053168 date "2013-10-01" @default.
- W1968053168 modified "2023-10-18" @default.
- W1968053168 title "Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment" @default.
- W1968053168 cites W178242959 @default.
- W1968053168 cites W18584794 @default.
- W1968053168 cites W1965679360 @default.
- W1968053168 cites W1970104053 @default.
- W1968053168 cites W1975206573 @default.
- W1968053168 cites W2002144368 @default.
- W1968053168 cites W2006011870 @default.
- W1968053168 cites W2009509017 @default.
- W1968053168 cites W2015148330 @default.
- W1968053168 cites W2015563925 @default.
- W1968053168 cites W2018230230 @default.
- W1968053168 cites W2022111057 @default.
- W1968053168 cites W2031800729 @default.
- W1968053168 cites W2038675571 @default.
- W1968053168 cites W2050694322 @default.
- W1968053168 cites W2063139303 @default.
- W1968053168 cites W2067705125 @default.
- W1968053168 cites W2089727509 @default.
- W1968053168 cites W2089908069 @default.
- W1968053168 cites W2092024345 @default.
- W1968053168 cites W2092651879 @default.
- W1968053168 cites W2093946039 @default.
- W1968053168 cites W2119888523 @default.
- W1968053168 cites W2128166983 @default.
- W1968053168 cites W2134595040 @default.
- W1968053168 cites W2147133758 @default.
- W1968053168 cites W2157039129 @default.
- W1968053168 cites W2163577777 @default.
- W1968053168 cites W2324172885 @default.
- W1968053168 cites W4211026375 @default.
- W1968053168 doi "https://doi.org/10.1016/j.jhep.2013.06.007" @default.
- W1968053168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23792029" @default.
- W1968053168 hasPublicationYear "2013" @default.
- W1968053168 type Work @default.
- W1968053168 sameAs 1968053168 @default.
- W1968053168 citedByCount "53" @default.
- W1968053168 countsByYear W19680531682013 @default.
- W1968053168 countsByYear W19680531682014 @default.
- W1968053168 countsByYear W19680531682015 @default.
- W1968053168 countsByYear W19680531682016 @default.
- W1968053168 countsByYear W19680531682017 @default.
- W1968053168 countsByYear W19680531682018 @default.
- W1968053168 countsByYear W19680531682019 @default.
- W1968053168 countsByYear W19680531682021 @default.
- W1968053168 countsByYear W19680531682022 @default.
- W1968053168 countsByYear W19680531682023 @default.
- W1968053168 crossrefType "journal-article" @default.
- W1968053168 hasAuthorship W1968053168A5029035458 @default.
- W1968053168 hasAuthorship W1968053168A5030193303 @default.
- W1968053168 hasAuthorship W1968053168A5031848511 @default.
- W1968053168 hasAuthorship W1968053168A5038617642 @default.
- W1968053168 hasAuthorship W1968053168A5066110089 @default.
- W1968053168 hasAuthorship W1968053168A5069529197 @default.
- W1968053168 hasAuthorship W1968053168A5083700089 @default.
- W1968053168 hasAuthorship W1968053168A5091803938 @default.
- W1968053168 hasConcept C126322002 @default.
- W1968053168 hasConcept C159654299 @default.
- W1968053168 hasConcept C203014093 @default.
- W1968053168 hasConcept C2522874641 @default.
- W1968053168 hasConcept C2775940106 @default.
- W1968053168 hasConcept C2777382497 @default.
- W1968053168 hasConcept C2777410769 @default.
- W1968053168 hasConcept C2777869810 @default.
- W1968053168 hasConcept C2779384505 @default.
- W1968053168 hasConcept C2780593183 @default.
- W1968053168 hasConcept C3020491458 @default.
- W1968053168 hasConcept C45189115 @default.
- W1968053168 hasConcept C71924100 @default.
- W1968053168 hasConcept C90924648 @default.
- W1968053168 hasConceptScore W1968053168C126322002 @default.
- W1968053168 hasConceptScore W1968053168C159654299 @default.
- W1968053168 hasConceptScore W1968053168C203014093 @default.
- W1968053168 hasConceptScore W1968053168C2522874641 @default.
- W1968053168 hasConceptScore W1968053168C2775940106 @default.
- W1968053168 hasConceptScore W1968053168C2777382497 @default.
- W1968053168 hasConceptScore W1968053168C2777410769 @default.
- W1968053168 hasConceptScore W1968053168C2777869810 @default.
- W1968053168 hasConceptScore W1968053168C2779384505 @default.
- W1968053168 hasConceptScore W1968053168C2780593183 @default.
- W1968053168 hasConceptScore W1968053168C3020491458 @default.
- W1968053168 hasConceptScore W1968053168C45189115 @default.
- W1968053168 hasConceptScore W1968053168C71924100 @default.
- W1968053168 hasConceptScore W1968053168C90924648 @default.
- W1968053168 hasIssue "4" @default.
- W1968053168 hasLocation W19680531681 @default.